Pharmaceuticals Russia

Russia AI in Drug Repurposing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Russia AI in Drug Repurposing Market Industry Trends and Forecast to 2034: Segmented by (Approach, Indication, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Russia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.5 Mn Placeholder estimate
Estimate 2025 $6.7 Mn 1.1% of the global market
Projected 2034 $39.7 Mn 494.3% Adds $33.1 Mn over 9 forecast years
CAGR 2025–2034 21.9% Faster than 91% of 163 Pharmaceuticals markets here
Key players 5
  • Russia is 1.12% of the global market.
  • In Europe, the largest is Germany at $24.4 Mn.
  • Fastest growing: Italy at 21.9% a year.
  • Russia ranks 6th of 6 by size in Europe.

Market size projection

Russia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$33.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
AI in Drug Repurposing Market market size by year, Russia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.5 Mn — —
2025 (base) $6.7 Mn +$1.2 Mn —
2026 (forecast) $8.2 Mn +$1.5 Mn +21.9%
2027 (forecast) $9.9 Mn +$1.8 Mn +48.6%
2028 (forecast) $12.1 Mn +$2.2 Mn +81.1%
2029 (forecast) $14.8 Mn +$2.7 Mn +120.8%
2030 (forecast) $18.0 Mn +$3.2 Mn +169.2%
2031 (forecast) $21.9 Mn +$3.9 Mn +228.1%
2032 (forecast) $26.7 Mn +$4.8 Mn +300%
2033 (forecast) $32.6 Mn +$5.9 Mn +387.6%
2034 (forecast) $39.7 Mn +$7.1 Mn +494.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Russia AI in Drug Repurposing Market Analysis at a glance
Market size, 2025$6.7 Mn placeholder estimate
Forecast, 2034$39.7 Mn placeholder estimate
Growth (CAGR), 2025–203421.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledArtificial Intelligence in Drug Repurposing
SegmentsApproach and indication (see all)
Key playersBenevolentAI, Healx, Insilico Medicine, Recursion Pharmaceuticals, Every Cure (see all)
Regulator in RussiaMinistry of HealthSource: Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Russia AI in Drug Repurposing Market Analysis Executive Summary

AI in drug repurposing searches data to find new uses for existing medicines, cutting the time and cost of development.

Key segments of the AI in Drug Repurposing market include approach (Knowledge Graphs, Machine Learning on Omics and Real-World Data Mining) and indication (Rare Diseases, Oncology and Infectious Diseases).

Bar chart: Russia AI in Drug Repurposing market size, 2024–2034, placeholder estimates. $5.5 Mn in 2024, $6.7 Mn in 2025 and $39.7 Mn in 2034, 21.9% CAGR.
Russia AI in Drug Repurposing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Russia AI in Drug Repurposing Market Dynamics

Market Growth Drivers

Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Drug Repurposing market. Health systems are moving from pilots to wider use.

Opportunity

Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Drug Repurposing market strong growth, including in emerging health systems.

Market Restraints

Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Drug Repurposing market.

Competitive Landscape for AI in Drug Repurposing Market in Russia

The AI in Drug Repurposing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for AI in Drug Repurposing Market in Russia

AI in Drug Repurposing in Russia: rules and payment

Medicines are registered by the Ministry of Health, under Eurasian Economic Union rules.⁠[1] Compulsory medical insurance (OMS) pays for a guaranteed package of free care, through the Federal Compulsory Medical Insurance Fund.⁠[2]

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AI in Drug Repurposing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Russia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in AI in Drug Repurposing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

AI in Drug Repurposing in context

Russia compared

  • Health spending per person: 1,003 US$ per person (2023). World: 1,317 US$ per person (2023). 12th highest of the 13 countries we cover in Europe.[1]
  • Doctors: 5.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 13 countries we cover in Europe.[2]
  • People aged 65 and over: 17.8% of people (2025). World: 10.4% of people (2025). 12th highest of the 13 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the AI in Drug Repurposing market in Russia?
Placeholder estimate: about $6.7 Mn in 2025, rising to about $39.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the AI in Drug Repurposing market in Russia growing?
Placeholder estimate: about 21.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the AI in Drug Repurposing market report cover?
The report splits the market by approach (Knowledge Graphs, Machine Learning on Omics, Real-World Data Mining) and indication (Rare Diseases, Oncology, Infectious Diseases, Neurology).
Who are the key players in the AI in Drug Repurposing market?
Key players include BenevolentAI, Healx, Insilico Medicine, Recursion Pharmaceuticals and Every Cure.
What is driving the AI in Drug Repurposing market?
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Drug Repurposing market. Health systems are moving from pilots to wider use.
Who regulates AI in Drug Repurposing in Russia?
Medicines are registered by the Ministry of Health, under Eurasian Economic Union rules. Source: Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
How is healthcare paid for in Russia?
Compulsory medical insurance (OMS) pays for a guaranteed package of free care, through the Federal Compulsory Medical Insurance Fund. Source: Federal Compulsory Medical Insurance Fund. Checked 14 Nov 2026.
How much research is published on AI in Drug Repurposing?
PubMed lists 1,006 papers on AI in Drug Repurposing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Russia

See all

Related on artificial intelligence and drug development and manufacturing

See the topic